Canaccord upgraded Mayne Pharma to Buy from Hold with a price target of A$6.69, up from A$3.80, after the company released its first half results. Positive trends across all segments are continuing and new management is well proving its ability to execute and to restore investor confidence in the longer-term sustainable growth story, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>